Streetbeat News

Revenues

HI

Hillenbrand (NYSE:HI) reported Q3 earnings of $0.85 per share, beating the analyst estimate of $0.82 but showing a decrease from $0.95 per share last year. Quarterly sales were $786.60 million, missing the $814.55 million estimate but increasing from $717.00 million last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 9:01 pm

REPX

Riley Exploration Permian (REPX) projects its Q3 total net production to be between 21-23 MBoe/d.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 9:01 pm

PHX

PHX Minerals has projected its total production for the fiscal year 2024 to be between 9,700 and 10,300 Mmcfe.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 9:01 pm

ENS

EnerSys has updated its financial outlook for Q2 and FY25, raising its EPS and revenue guidance. The company expects Q2 EPS to be between $2.05 and $2.15, and revenue between $880M and $920M. For FY25, EPS guidance has been raised to $8.80-$9.20, and revenue to $3.735B-$3.885B. The updates reflect the benefits of the Bren-Tronics acquisition and positive demand trends in most end markets.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 9:01 pm

VTLE

Vital Energy (NYSE:VTLE) reported Q2 2024 earnings per share (EPS) of $1.46, missing the analyst consensus estimate of $1.84 by 20.65%. However, the company reported quarterly sales of $476.370 million, beating the analyst consensus estimate of $472.884 million by 0.74%. This represents a 42.17% increase over sales of $335.062 million in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 9:01 pm

STE

In the past three months, four analysts have provided ratings for Steris (NYSE:STE), with the majority being somewhat bullish. The average 12-month price target is $253.75, slightly up from the previous $252.50. Analysts have maintained or raised their ratings, reflecting positive sentiment. Steris has shown solid revenue growth but faces challenges in profitability and return metrics.

Portfolio Pulse from Benzinga Insights

August 07, 2024 | 9:00 pm

PFLT

PennantPark Floating Rate (NYSE:PFLT) reported Q3 2024 adjusted EPS of $0.31, missing the $0.32 estimate by 3.13%. However, sales of $48.505M beat the $45.100M estimate by 7.55%, marking a 28.62% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 9:00 pm

CHRD

Chord Energy (NASDAQ:CHRD) has significantly outperformed the market over the past 5 years, with an annualized return of 107.54% and an average annual return of 119.68%. A $100 investment in CHRD 5 years ago would be worth $5,185.14 today. The company's current market capitalization is $9.57 billion.

Portfolio Pulse from Benzinga Insights

August 07, 2024 | 9:00 pm

BCYC

Analysts have provided mixed ratings for Bicycle Therapeutics (NASDAQ:BCYC) over the past three months, with a majority being bullish. The average 12-month price target is $42.25, slightly down from the previous $43.50. Key analysts have maintained their ratings, with one lowering the price target. Bicycle Therapeutics has shown significant revenue growth but faces challenges in ROE and ROA.

Portfolio Pulse from Benzinga Insights

August 07, 2024 | 9:00 pm

MCHP

Microchip Technology (NASDAQ:MCHP) has outperformed the market over the past 10 years, delivering an average annual return of 11.95%. A $1000 investment in MCHP 10 years ago would be worth $3,112.17 today. The article highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

August 07, 2024 | 9:00 pm